{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:ema.welireg:0 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Aema.welireg%3A0",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.004713,
    "timestamp_received": "2026-05-09T05:47:17.284801+00:00Z",
    "timestamp_returned": "2026-05-09T05:47:17.289514+00:00Z",
    "trace_id": "64ec00f9-b292-4938-8f8e-84c753ba7fab"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-05-07"
  },
  "data": [
    {
      "id": "ind:ema.welireg:0",
      "indication": "Welireg is indicated as monotherapy for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated, localised renal cell carcinoma (RCC), central nervous system (CNS) haemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable.",
      "initial_approval_date": "2025-02-12",
      "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/welireg-epar-public-assessment-report_en.pdf",
      "description": "The European Medicines Agency (EMA) has authorized belzutifan as a monotherapy for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated, localized renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable. This indication is based on LITESPARK-004, an open-label phase 2 clinical study in 61 patients with VHL disease who had at least one measurable solid tumor localized to the kidney and who did not require immediate surgery. Patients could also have other VHL disease-associated tumors such as CNS hemangioblastomas and pNETs. VHL-associated disease was based on the presence of a VHL germline alteration.",
      "raw_biomarkers": "von Hippel-Lindau disease",
      "raw_cancer_type": "renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET)",
      "raw_therapeutics": "Welireg (belzutifan)",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:ema.welireg",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Welireg (belzutifan) [product information]. EMA.",
        "title": null,
        "aliases": [],
        "description": "Merck Sharp & Dohme B.V. Welireg (belzutifan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/welireg-epar-product-information_en.pdf.pdf. Revised January 2026. Accessed May 5, 2026.",
        "urls": [
          "https://www.ema.europa.eu/en/medicines/human/EPAR/welireg",
          "https://www.ema.europa.eu/en/documents/product-information/welireg-epar-product-information_en.pdf"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "ema",
              "type": "Agent",
              "agentType": "organization",
              "name": "European Medicines Agency",
              "description": "Regulatory agency that approves medicines for use in the European Union.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2026-05-05",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://www.ema.europa.eu/en/medicines",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "Merck Sharp & Dohme B.V.",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": "Welireg",
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": "belzutifan",
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": "2025-02-27",
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": "EMEA/H/C/005636",
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2026-01-13",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}